Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register

Abstract

The Haemostasis Registry cannot replace well-designed prospective randomized controlled trials, but in their absence this registry provides a basis for understanding current clinical experience of rFVIIa. Registries continue to be vital in monitoring off-label uses of medications.